1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
Daiichi Sankyo said on May 16 that it will divest its generic subsidiary, Daiichi Sankyo Espha, to major pharmacy chain operator Qol Holdings for 25 billion yen. The drug maker’s board of directors hammered out a resolution to transfer the…
To read the full story
Related Article
BUSINESS
- Lilly Japan Fostering Better Understanding of Health Issues to Retain Female Reps
February 26, 2025
- Seikagaku Kicks Off Japan PIII for Osteoarthritis Drug Gel-One
February 26, 2025
- Shonan iPark to Drive Japan Approval of New Drugs from Korean Biotechs
February 26, 2025
- Building New Plant in US Is Not a Solution to Potential Tariffs: Astellas CEO
February 25, 2025
- J&J to Terminate Business with Wholesaler Toho
February 25, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…